ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence supporting comparability and establish the basis for AEON’s planned multi-lot comparability study ALISO VIEJO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to